| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
127,390,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. Co.'s existing pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus, influenza A virus, and human immunodeficiency virus. Co. has collaborate with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. to focus on treating and preventing severe acute respiratory syndrome coronavirus 2 (the virus that causes COVID-19 illness). Co. is developing differentiated monoclonal antibodies, like sotrovimab and VIR-7832, as well as vaccines and small molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$246,341 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
136,328 |
167,399 |
782,068 |
6,005,613 |
| Total Sell Value |
$1,354,144 |
$1,671,921 |
$17,840,473 |
$153,953,368 |
| Total People Sold |
5 |
5 |
9 |
11 |
| Total Sell Transactions |
7 |
10 |
24 |
123 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Parrish Jay |
Chief Business Officer |
• – – |
2021-03-01 |
4 |
OE |
$1.49 |
$10,520 |
D/D |
6,944 |
16,204 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-02-23 |
4 |
AS |
$63.74 |
$503,577 |
D/D |
(7,900) |
74,200 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-02-23 |
4 |
OE |
$1.53 |
$28,917 |
D/D |
18,900 |
82,100 |
|
- |
|
| Scangos George A |
President and CEO |
• • – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
111,000 |
4,609,559 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
63,200 |
|
- |
|
| Horn Howard |
CFO |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
202,777 |
|
- |
|
| Rice Steven J. |
Chief Administrative Officer |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
109,277 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-02-16 |
4 |
OE |
$0.86 |
$8,550 |
D/D |
10,000 |
77,277 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-02-12 |
4 |
OE |
$0.86 |
$8,550 |
D/D |
10,000 |
67,277 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-02-09 |
4 |
AS |
$71.16 |
$562,161 |
D/D |
(7,900) |
33,200 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-02-09 |
4 |
OE |
$1.53 |
$12,087 |
D/D |
7,900 |
41,100 |
|
- |
|
| Parrish Jay |
Chief Business Officer |
• – – |
2021-02-01 |
4 |
AS |
$69.91 |
$485,424 |
D/D |
(6,944) |
222,222 |
|
- |
|
| Parrish Jay |
Chief Business Officer |
• – – |
2021-02-01 |
4 |
OE |
$1.49 |
$10,729 |
D/D |
6,944 |
229,166 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-01-26 |
4 |
AS |
$48.17 |
$1,507,806 |
D/D |
(31,300) |
33,200 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-01-26 |
4 |
OE |
$1.53 |
$47,889 |
D/D |
31,300 |
64,500 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-01-15 |
4 |
AS |
$38.00 |
$400,140 |
D/D |
(10,530) |
33,200 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-01-15 |
4 |
OE |
$1.53 |
$16,111 |
D/D |
10,530 |
43,730 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-01-12 |
4 |
AS |
$29.36 |
$111,696 |
D/D |
(3,805) |
33,200 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-01-12 |
4 |
OE |
$1.53 |
$5,822 |
D/D |
3,805 |
37,005 |
|
- |
|
| Parrish Jay |
Chief Business Officer |
• – – |
2021-01-04 |
4 |
AS |
$26.32 |
$182,795 |
D/D |
(6,945) |
222,222 |
|
- |
|
| Parrish Jay |
Chief Business Officer |
• – – |
2021-01-04 |
4 |
OE |
$1.49 |
$10,313 |
D/D |
6,945 |
229,167 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2020-12-24 |
4 |
OE |
$1.53 |
$14,535 |
D/D |
9,500 |
33,200 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2020-12-22 |
4 |
AS |
$31.19 |
$118,683 |
D/D |
(3,805) |
23,700 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2020-12-22 |
4 |
OE |
$1.53 |
$5,822 |
D/D |
3,805 |
27,505 |
|
- |
|
575 Records found
|
|
Page 18 of 23 |
|
|
